TELA Bio (TELA) Q1 2026 earnings review
Growth Hits a Wall as Mix Shift Crushes ASPs
TELA Bio's narrative of a 'fully built' commercial foundation translating into execution is sharply contradicted by its Q1 data. Total revenue grew a paltry 3% YoY to $19.1 million, a massive deceleration from the 18% growth posted just one quarter ago. While underlying unit volume increased 13%, a severe shift toward smaller-sized units in the U.S. obliterated average selling prices (ASPs). Furthermore, Q2 guidance of $20.0 million implies a ~1% YoY contraction. To hit the reiterated full-year guidance of 'at least 8% growth,' management is banking on a heroic, high-risk acceleration in the second half of the year.
🐂 Bull Case
Operating expenses were held flat at $23.0 million compared to the prior year. Management noted the commercial team is fully staffed, meaning top-line growth (if it returns) should flow through to the bottom line.
European revenue accelerated significantly, posting 41% YoY growth. The U.K. footprint is expanding, and early traction in additional markets demonstrates the product's viability overseas.
🐻 Bear Case
With total revenue up only 3% and Europe up 41%, the math dictates that the core U.S. business is flat to slightly down. The rapid mix shift toward smaller, cheaper units for robotic procedures is neutralizing volume gains.
Gross margin compressed 190 basis points to 65.7% due to excess and obsolete inventory charges. The company burned $11.3M in cash in Q1, leaving just $39.5M against $55.9M in long-term debt.
⚖️ Verdict: 🔴🔴
Very Bearish. The headline 3% growth is alarming, but the Q2 guidance implying negative YoY growth is the true red flag. The combination of structural ASP headwinds, compressing margins, and a heavy reliance on a second-half hockey stick creates an extremely poor setup for investors.
Key Themes
The Decoupling of Volume and Revenue
The 1,000 basis point gap between unit growth (+13%) and revenue growth (+3%) illustrates a severe ASP problem. Management attributes this to a product mix headwind in the U.S. related to 'the rapid growth of smaller-sized units.' As surgeons continue migrating toward robotic and minimally invasive procedures that require smaller mesh pieces, this mix shift may represent a permanent structural reset to TELA's revenue model rather than a temporary blip.
Margin Compression Driven by Inventory Waste
Gross profit margins fell from 67.6% in 25Q1 to 65.7% in 26Q1. Strikingly, management explicitly cited 'a higher charge for excess and obsolete inventory as a percentage of revenue' as the primary cause. This suggests poor demand forecasting or product transitions stranding older inventory, an operational inefficiency that cannot be ignored for a cash-burning company.
European Market Acceleration
The international business was the sole top-line savior in the quarter, accelerating to 41% YoY growth. Management highlighted continued momentum in the U.K. and early expansion into new European geographies. While still a smaller portion of the overall business, it is providing a critical buffer against U.S. domestic weakness.
OviTex LTR Launch Fills Portfolio Gap
On April 1st, TELA initiated the full U.S. commercial launch of OviTex LTR, marketed as one of the only fully resorbable, tissue-based hernia repair solutions available. This expands the portfolio's total addressable market by capturing surgeons who refuse to implant any permanent polymer. How quickly the newly staffed sales cohort can drive adoption of this specific product will heavily dictate the second-half recovery.
Cost Cutting Disguised as 'De Minimis' Increases
Total operating expenses were perfectly flat YoY at $23.0 million. However, the composition changed: compensation and commission expenses fell, while professional fees, meeting, and training costs rose. Falling commissions align with the stalled top-line growth, indicating that the 'fully staffed' sales force is currently under-earning compared to prior periods. This poses a potential flight-risk for high-performing reps.
Other KPIs
Down dramatically from $50.8 million at the end of 2025. The company burned $11.3 million in cash during the quarter. With long-term debt sitting at $55.9 million, the balance sheet is becoming a constraint. If cash burn remains near $10M+ per quarter, TELA will be forced to raise highly dilutive capital before the end of the year.
Flat compared to $(10.5) million in the prior year period. While holding OpEx steady kept the bleeding from worsening, the lack of top-line scale means TELA is no closer to profitability today than it was a year ago.
Guidance
Reversing. Based on 25Q2 reported revenue of $20.2 million, this guidance implies a roughly 1% YoY contraction. This is a severe deceleration from the already disappointing +3% posted in Q1, raising serious questions about near-term demand stability in the U.S. market.
Stable (but highly questionable). To achieve 8% annual growth over FY25's $80.3M, FY26 revenue must hit ~$86.7M. With Q1 actuals ($19.1M) and Q2 guidance ($20.0M) summing to just $39.1M for H1, TELA will need to generate ~$47.6M in H2. This requires an improbable 22%+ YoY growth rate in the back half of the year, relying heavily on unprecedented new rep productivity and the OviTex LTR ramp.
Key Questions
The Math on the Second-Half Hockey Stick
With Q1 delivering 3% growth and Q2 guidance implying negative growth, reaching your 8% full-year target requires >20% growth in the second half. What specific, measurable catalysts give you confidence in this extreme acceleration?
Establishing an ASP Floor
Given the 10 percentage point divergence between unit volume and revenue growth, at what point does the mix shift toward smaller, robotic-compatible units plateau, and what is the new baseline ASP we should model?
Inventory Obsolescence Dynamics
You cited excess and obsolete inventory charges as the primary drag on gross margin. Was this a one-time write-down related to transitioning hospital accounts to new products like OviTex LTR, or is this a recurring structural issue in your supply chain?
Capital Needs and Liquidity
With $39.5M in cash, $55.9M in debt, and quarterly burn exceeding $10M, how do you plan to bridge the business to cash-flow break-even without executing a highly dilutive equity raise?